ĐÁNH GIÁ KẾT QUẢ KIỂM SOÁT CẬN THỊ Ở TRẺ EM BẰNG ATROPIN 0,05% TẠI BỆNH VIỆN MẮT HÀ NỘI

Abstract

Introduction: Childhood myopia is increasing rapidly worldwide, particularly in Asia, leading

to an elevated risk of dangerous complications. Atropine 0.05% has been proven effective in controlling myopia progression globally, but evidence in Vietnam remains limited. Objective: To evaluate the initial outcomes of myopia control in children using atropine 0.05% at Hanoi Eye Hospital. Subjects and Methods: A retrospective case series study on 24 pediatric patients (48 eyes) aged 6-15 years, diagnosed with rapid progressive myopia or at high risk, treated with atropine 0.05% and followed up for at least 24 months at Hanoi Eye Hospital from October 2024 to February 2025. Results: After 24 months, the mean spherical equivalent (SE) increased from -4.30 D to -4.89 D; the mean axial length (AL) increased from 25.13 mm to 25.25 mm. The proportion of eyes with a slow axial elongation rate reached 93.8% (p<0.001). The rate of successful control according to the World Myopia Institute criteria was 58.3% after 24 months. Pupil size increased by only approximately 1mm, indicating that atropine did not cause excessive pupil dilation, and the decrease in accommodative amplitude enhanced patient tolerability to atropine. Conclusion:Atropine 0.05% is an effective measure for controlling myopia progression in children, particularly with long-term use over 24 months.